Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
The VANGUARD coordinator, Ekaterine Berishvili together with Charles-Henri Wassmer have recently published a new article in Current Diabetes Reports on the Immunomodulatory Properties of Amniotic
More than 40 million individuals worldwide are affected by type 1 diabetes, which is the most common chronic disease in children and adolescents. Today’s primary
Representatives from the eight VANGUARD partners travelled from across Europe to Igls in Austria to officially kick-off the project. The meeting took place on the